Zobrazeno 1 - 10
of 207
pro vyhledávání: '"Alvaro Moreno, Aspitia"'
Autor:
Xiaojia Tang, Kevin J. Thompson, Krishna R. Kalari, Jason P. Sinnwell, Vera J. Suman, Peter T. Vedell, Sarah A. McLaughlin, Donald W. Northfelt, Alvaro Moreno Aspitia, Richard J. Gray, Jodi M. Carter, Richard Weinshilboum, Liewei Wang, Judy C. Boughey, Matthew P. Goetz
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-18 (2023)
Abstract Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Patients with TNBC are primarily treated with neoadjuvant chemotherapy (NAC). The response to NAC is prognostic, with reductions in overall surviva
Externí odkaz:
https://doaj.org/article/3af3f74d177a4754a631cf8c8eef5d57
Autor:
Jennifer Berrian, Ying Liu, Nkiruka Ezenwajiaku, Alvaro Moreno‐Aspitia, Sara J. Holton, Adetunji T. Toriola, Graham A. Colditz, Ashley J. Housten, Lannis Hall, Mark A. Fiala, Foluso O. Ademuyiwa
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7381-7388 (2023)
Abstract Purpose To determine if the COVID‐19 pandemic has further exacerbated racial disparities in late‐stage presentation of breast, colorectal, lung, and prostate cancers. Methods We conducted a registry‐based retrospective study of patient
Externí odkaz:
https://doaj.org/article/1d0cb9ad009d4c1a902d1ad3c26a0f94
Autor:
Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. Weirather, Anita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemothera
Externí odkaz:
https://doaj.org/article/d2b06f8f41a040519a09fe040f35b01e
Autor:
Elisa Agostinetto, Lieveke Ameye, Samuel Martel, Philippe Aftimos, Noam Pondé, Christian Maurer, Sarra El-Abed, Yingbo Wang, Malou Vicente, Saranya Chumsri, Judith Bliss, Judith Kroep, Marco Colleoni, Fausto Petrelli, Lucia Del Mastro, Alvaro Moreno-Aspitia, Martine Piccart, Marianne Paesmans, Evandro de Azambuja, Matteo Lambertini
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic perfo
Externí odkaz:
https://doaj.org/article/26e9c2c289cb4f0e805a3be45e4ff06d
Autor:
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Amylou C. Dueck, Christos Sotiriou, Cristina Saura, Alvaro Moreno-Aspitia, Keith L. Knutson, Edith A. Perez, E. Aubrey Thompson
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the role of the imm
Externí odkaz:
https://doaj.org/article/c541e25cb1954a448e8d1d99ad81395d
Autor:
Saranya Chumsri, MD, Pooja P. Advani, MD, Tanmayi S. Pai, MD, Zhuo Li, MS, Ashita Mummareddy, Marites Acampora, APRN, Gina A. Reynolds, APRN, Natasha Wylie, APRN, Ashton W. Boyle, Yanyan Lou, MD, PhD, Kabir Mody, MD, Alvaro Moreno-Aspitia, MD, Melanie D. Swift, MD, MPH, Abinash Virk, MD, Adil E. Bharucha, MD, Christopher P. Marquez, MD, Tushar C. Patel, MD, Gregory J. Gores, MD, Keith L. Knutson, PhD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 6, Iss 2, Pp 120-125 (2022)
Objective: To evaluate the magnitude of humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with cancer receiving active therapies. Patients and Methods: Patients 18 years or olde
Externí odkaz:
https://doaj.org/article/c346308a1a534e438fccc0f0a7479d5d
Autor:
Kurt A. Jaeckle, Jesse G. Dixon, Stephen Keith Anderson, Alvaro Moreno‐Aspitia, Gerardo Colon‐Otero, Kathy Hebenstreit, Tejal A. Patel, Samarth L. Reddy, Edith A. Perez
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 7935-7942 (2020)
Abstract Background There are few treatment options for patients with leptomeningeal metastases (LM). Methods We report a case series of patients with breast cancer and LM treated with intra‐CSF topotecan (TOPO). Outcome was assessed by clinical ex
Externí odkaz:
https://doaj.org/article/084679dd348a4b969ff1555cfe063527
Autor:
Umair Majeed, Tudor Puiu, Jason Sluzevich, Gina Reynolds, Marites Acampora, Alvaro Moreno-Aspitia, Katherine J. Bodiford, Pooja Advani
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Alpelisib is a PIK3a inhibitor approved for the treatment of metastatic ER+ breast cancer in combination with fulvestrant. Although rash is a common side effect of this medication, we present the first case of drug reaction with eosinophilia and syst
Externí odkaz:
https://doaj.org/article/e8c1359fb89447618c412fdd3e63f7c0
Autor:
Saranya Chumsri, Zhuo Li, Nadine Norton, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Keith L. Knutson, Antonio C. Wolff, Edith A. Perez, E. A. Thompson
Publikováno v:
Cancer Research. 83:P2-11
Background: We previously demonstrated that intrinsic subtypes were associated with prognosis for early recurrence risk in patients (pts) with early-stage HER2-positive (HER2+) BC treated with trastuzumab (H) in the N9831 trial. Here, we evaluated th
Autor:
Kaylee Clark, Jamie L. Carroll, Alvaro Moreno-Aspitia, Brenda Ernst, Farah Raheem, Ashley Heil, Beth Boyer, Kristin Mara, Matthew P. Goetz, Roberto A. Leon-Ferre, Karthik V. Giridhar, Jodi Taraba
Publikováno v:
Cancer Research. 83:P4-07
Background: SG was approved in 2020 for the treatment of metastatic triple negative breast cancer (TNBC). The most common grade 3/4 adverse event in the ASCENT trial was neutropenia (51.2%) with a 6% incidence of febrile neutropenia. 1 Package insert